Compare United States Oil ETF (USO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Oil ETF vs GeneDx Holdings Corp — how do they compare? United States Oil ETF trades at $147.49 (market cap $1.90B), while GeneDx Holdings Corp trades at $67.72 (market cap $2.02B). The key difference: United States Oil ETF and GeneDx Holdings Corp are close in size by market cap, and United States Oil ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Oil ETF for 21 Days and GeneDx Holdings Corp for 19 Days on average.
| USO | WGS | |
|---|---|---|
Market Cap | $1.90B | $2.02B |
Volume | 5,932,922 | 734,640 |
52-Week High | $161.86 | $167.51 |
52-Week Low | $66.17 | $34.51 |
Typical Hold Time | 21 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USO is trading at $147.835, up 2.73% with a bullish technical signal from moving averages. The stock shows neutral oscillators but faces mixed oil market conditions with Middle East tensions and G-7 reserve releases creating volatility. Recent news highlights supply disruptions and geopolitical risks affecting crude prices.
The outlook remains cautious with geopolitical risks and supply uncertainties balancing against potential price support from production constraints. Investment opportunities exist if supply disruptions persist, but risks include regulatory pressures and volatile oil markets that could impact shareholder value.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
